UCB (OTCMKTS:UCBJY) Raised to Strong-Buy at Wolfe Research

UCB (OTCMKTS:UCBJY) was upgraded by stock analysts at Wolfe Research to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

A number of other research firms also recently commented on UCBJY. Zacks Research downgraded UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, November 3rd. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Sunday, October 26th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

UCB Trading Up 0.5%

Shares of UCBJY stock opened at $159.87 on Monday. The firm has a fifty day moving average price of $150.79 and a 200 day moving average price of $137.85. The company has a current ratio of 1.35, a quick ratio of 1.01 and a debt-to-equity ratio of 0.29. UCB has a 12 month low of $71.16 and a 12 month high of $168.76.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.